Ranked listPublic

Public Companies Ranked by R&D Intensity

Major public companies ranked by annual research and development expense as a percentage of same-period annual revenue. Requires at least $1B annual revenue. Calculated by Podium Atlas from SEC company facts. Official-data ranked list; not financial advice. Includes annual reporting periods ending from July 2025 through July 2026. Refreshed weekly from SEC Company Facts.

By PodiumBot73 itemsUpdated Sep 6, 2026

Creator list

Ranked order

73 items

1

A—

ARM — Arm Holdings

R&D / revenue56.4%

R&D expense equaled 56.4% of annual revenue ($2.8B of $4.9B) for the reporting period ending March 2026. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

2

S—

SNPS — Synopsys

R&D / revenue35.1%

R&D expense equaled 35.1% of annual revenue ($2.5B of $7.1B) for the reporting period ending October 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

3

M—

META — Meta Platforms

R&D / revenue28.5%

R&D expense equaled 28.5% of annual revenue ($57.4B of $201.0B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

4

I—

INTC — Intel

R&D / revenue26.1%

R&D expense equaled 26.1% of annual revenue ($13.8B of $52.9B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

5

M—

MRVL — Marvell Technology

R&D / revenue25.3%

R&D expense equaled 25.3% of annual revenue ($2.1B of $8.2B) for the reporting period ending January 2026. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

6

M—

MRK — Merck

R&D / revenue24.3%

R&D expense equaled 24.3% of annual revenue ($15.8B of $65.0B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

7

A—

AMD — Advanced Micro Devices

R&D / revenue23.4%

R&D expense equaled 23.4% of annual revenue ($8.1B of $34.6B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

8

N—

NOW — ServiceNow

R&D / revenue22.3%

R&D expense equaled 22.3% of annual revenue ($3.0B of $13.3B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

9

P—

PANW — Palo Alto Networks

R&D / revenue21.5%

R&D expense equaled 21.5% of annual revenue ($2.0B of $9.2B) for the reporting period ending July 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

10

B—

BMY — Bristol Myers Squibb

R&D / revenue20.6%

R&D expense equaled 20.6% of annual revenue ($10.0B of $48.2B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

11

Q—

QCOM — Qualcomm

R&D / revenue20.4%

R&D expense equaled 20.4% of annual revenue ($9.0B of $44.3B) for the reporting period ending September 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

12

A—

AVGO — Broadcom

R&D / revenue17.2%

R&D expense equaled 17.2% of annual revenue ($11.0B of $63.9B) for the reporting period ending November 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

13

A—

ADI — Analog Devices

R&D / revenue16.0%

R&D expense equaled 16.0% of annual revenue ($1.8B of $11.0B) for the reporting period ending November 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

14

I—

INTU — Intuit

R&D / revenue15.5%

R&D expense equaled 15.5% of annual revenue ($2.9B of $18.8B) for the reporting period ending July 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

15

O—

ORCL — Oracle

R&D / revenue15.3%

R&D expense equaled 15.3% of annual revenue ($10.3B of $67.4B) for the reporting period ending May 2026. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

16

G—

GOOGL — Alphabet

R&D / revenue15.2%

R&D expense equaled 15.2% of annual revenue ($61.1B of $402.8B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

17

C—

CSCO — Cisco Systems

R&D / revenue15.1%

R&D expense equaled 15.1% of annual revenue ($9.6B of $63.3B) for the reporting period ending July 2026. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

18

E—

EBAY — eBay

R&D / revenue14.8%

R&D expense equaled 14.8% of annual revenue ($1.6B of $11.1B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

19

C—

CRM — Salesforce

R&D / revenue14.4%

R&D expense equaled 14.4% of annual revenue ($6.0B of $41.5B) for the reporting period ending January 2026. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

20

A—

ANET — Arista Networks

R&D / revenue13.7%

R&D expense equaled 13.7% of annual revenue ($1.2B of $9.0B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

21

S—

SHOP — Shopify

R&D / revenue13.3%

R&D expense equaled 13.3% of annual revenue ($1.5B of $11.6B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

22

I—

ISRG — Intuitive Surgical

R&D / revenue13.0%

R&D expense equaled 13.0% of annual revenue ($1.3B of $10.1B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

23

A—

AMAT — Applied Materials

R&D / revenue12.6%

R&D expense equaled 12.6% of annual revenue ($3.6B of $28.4B) for the reporting period ending October 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

24

P—

PLTR — Palantir Technologies

R&D / revenue12.5%

R&D expense equaled 12.5% of annual revenue ($557.7M of $4.5B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

25

I—

IBM — IBM

R&D / revenue12.3%

R&D expense equaled 12.3% of annual revenue ($8.3B of $67.5B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

26

F—

FTNT — Fortinet

R&D / revenue12.0%

R&D expense equaled 12.0% of annual revenue ($815.5M of $6.8B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

27

T—

TXN — Texas Instruments

R&D / revenue11.8%

R&D expense equaled 11.8% of annual revenue ($2.1B of $17.7B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

28

K—

KLAC — KLA

R&D / revenue11.3%

R&D expense equaled 11.3% of annual revenue ($1.5B of $13.6B) for the reporting period ending June 2026. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

29

M—

MSFT — Microsoft

R&D / revenue10.7%

R&D expense equaled 10.7% of annual revenue ($35.6B of $331.8B) for the reporting period ending June 2026. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

30

L—

LRCX — Lam Research

R&D / revenue10.2%

R&D expense equaled 10.2% of annual revenue ($2.4B of $23.2B) for the reporting period ending June 2026. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

31

M—

MU — Micron Technology

R&D / revenue10.2%

R&D expense equaled 10.2% of annual revenue ($3.8B of $37.4B) for the reporting period ending August 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

32

N—

NVDA — NVIDIA

R&D / revenue8.6%

R&D expense equaled 8.6% of annual revenue ($18.5B of $215.9B) for the reporting period ending January 2026. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

33

A—

AAPL — Apple

R&D / revenue8.3%

R&D expense equaled 8.3% of annual revenue ($34.5B of $416.2B) for the reporting period ending September 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

34

A—

ADSK — Autodesk

R&D / revenue8.2%

R&D expense equaled 8.2% of annual revenue ($409.0M of $5.0B) for the reporting period ending April 2026. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

35

N—

NFLX — Netflix

R&D / revenue7.5%

R&D expense equaled 7.5% of annual revenue ($3.4B of $45.2B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

36

T—

TSLA — Tesla

R&D / revenue6.8%

R&D expense equaled 6.8% of annual revenue ($6.4B of $94.8B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

37

A—

ABT — Abbott Laboratories

R&D / revenue6.6%

R&D expense equaled 6.6% of annual revenue ($2.9B of $44.3B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

38

U—

UBER — Uber

R&D / revenue6.5%

R&D expense equaled 6.5% of annual revenue ($3.4B of $52.0B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

39

D—

DHR — Danaher

R&D / revenue6.5%

R&D expense equaled 6.5% of annual revenue ($1.6B of $24.6B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

40

B—

BABA — Alibaba Group

R&D / revenue6.5%

R&D expense equaled 6.5% of annual revenue ($9.6B of $148.4B) for the reporting period ending March 2026. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

41

V—

VRSN — Verisign

R&D / revenue6.3%

R&D expense equaled 6.3% of annual revenue ($103.6M of $1.7B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

42

S—

STX — Seagate Technology

R&D / revenue6.2%

R&D expense equaled 6.2% of annual revenue ($755.0M of $12.2B) for the reporting period ending July 2026. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

43

G—

GLW — Corning

R&D / revenue5.1%

R&D expense equaled 5.1% of annual revenue ($800.0M of $15.6B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

44

D—

DE — Deere

R&D / revenue5.1%

R&D expense equaled 5.1% of annual revenue ($2.3B of $45.7B) for the reporting period ending November 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

45

A—

ADP — Automatic Data Processing

R&D / revenue4.7%

R&D expense equaled 4.7% of annual revenue ($1.0B of $21.9B) for the reporting period ending June 2026. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

46

V—

VRT — Vertiv

R&D / revenue4.3%

R&D expense equaled 4.3% of annual revenue ($441.7M of $10.2B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

47

C—

CMI — Cummins

R&D / revenue4.1%

R&D expense equaled 4.1% of annual revenue ($1.4B of $33.7B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

48

A—

APP — AppLovin

R&D / revenue4.1%

R&D expense equaled 4.1% of annual revenue ($226.5M of $5.5B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

49

B—

BA — Boeing

R&D / revenue4.0%

R&D expense equaled 4.0% of annual revenue ($3.6B of $89.5B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

50

P—

PDD — PDD Holdings

R&D / revenue3.8%

R&D expense equaled 3.8% of annual revenue ($2.4B of $61.8B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

51

G—

GE — General Electric

R&D / revenue3.4%

R&D expense equaled 3.4% of annual revenue ($1.6B of $45.9B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

52

C—

CAT — Caterpillar

R&D / revenue3.2%

R&D expense equaled 3.2% of annual revenue ($2.1B of $67.6B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

53

R—

RTX — RTX

R&D / revenue3.2%

R&D expense equaled 3.2% of annual revenue ($2.8B of $88.6B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

54

G—

GEV — GE Vernova

R&D / revenue3.1%

R&D expense equaled 3.1% of annual revenue ($1.2B of $38.1B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

55

T—

TMO — Thermo Fisher Scientific

R&D / revenue3.1%

R&D expense equaled 3.1% of annual revenue ($1.4B of $44.6B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

56

E—

ETN — Eaton

R&D / revenue2.9%

R&D expense equaled 2.9% of annual revenue ($797.0M of $27.4B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

57

A—

APH — Amphenol

R&D / revenue2.8%

R&D expense equaled 2.8% of annual revenue ($647.0M of $23.1B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

58

E—

EA — Electronic Arts

R&D / revenue2.8%

R&D expense equaled 2.8% of annual revenue ($105.1M of $3.8B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

59

D—

DELL — Dell Technologies

R&D / revenue2.8%

R&D expense equaled 2.8% of annual revenue ($3.1B of $113.5B) for the reporting period ending January 2026. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

60

L—

LMT — Lockheed Martin

R&D / revenue2.7%

R&D expense equaled 2.7% of annual revenue ($2.0B of $75.0B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

61

P—

PG — Procter & Gamble

R&D / revenue2.4%

R&D expense equaled 2.4% of annual revenue ($2.1B of $87.0B) for the reporting period ending June 2026. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

62

P—

PM — Philip Morris International

R&D / revenue1.9%

R&D expense equaled 1.9% of annual revenue ($756.0M of $40.6B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

63

T—

TT — Trane Technologies

R&D / revenue1.6%

R&D expense equaled 1.6% of annual revenue ($347.6M of $21.3B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

64

P—

PH — Parker-Hannifin

R&D / revenue1.2%

R&D expense equaled 1.2% of annual revenue ($267.0M of $21.5B) for the reporting period ending June 2026. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

65

P—

PEP — PepsiCo

R&D / revenue0.9%

R&D expense equaled 0.9% of annual revenue ($839.0M of $93.9B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

66

M—

MO — Altria

R&D / revenue0.8%

R&D expense equaled 0.8% of annual revenue ($195.0M of $23.3B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

67

N—

NEM — Newmont

R&D / revenue0.7%

R&D expense equaled 0.7% of annual revenue ($166.0M of $22.7B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

68

H—

HWM — Howmet Aerospace

R&D / revenue0.4%

R&D expense equaled 0.4% of annual revenue ($37.0M of $8.3B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

69

L—

LIN — Linde

R&D / revenue0.4%

R&D expense equaled 0.4% of annual revenue ($147.0M of $34.0B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

70

X—

XOM — Exxon Mobil

R&D / revenue0.4%

R&D expense equaled 0.4% of annual revenue ($1.2B of $332.2B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

71

C—

CVX — Chevron

R&D / revenue0.2%

R&D expense equaled 0.2% of annual revenue ($427.0M of $184.4B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

72

C—

COP — ConocoPhillips

R&D / revenue0.2%

R&D expense equaled 0.2% of annual revenue ($78.0M of $51.8B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.

73

J—

JNJ — Johnson & Johnson

R&D / revenue0.1%

R&D expense equaled 0.1% of annual revenue ($109.0M of $94.2B) for the reporting period ending December 2025. Calculated by Podium Atlas from SEC Company Facts; not financial advice.